Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, achieved a significant milestone related to its lead investigational product early this year.
On Jan.22, 2024, the company announced that the FDA has accepted its Biologics License Application for Obecabtagene autoleucel for patients with relapsed/refractory Adult B-Cell Acute Lymphoblastic Leukemia, with a decision date set for November 16, 2024.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.